NCT06067256Unknown4 期
A Multicentre, Prospective, Open-label, Non-comparative Study to Evaluate Menstrual Bleeding Typology, Tolerability, and Compliance During a Monophasic Hormonal Contraceptive Treatment With Norgestimate + Ethinylestradiol in Italy.
Italfarmaco1 个研究点 分布在 1 个国家目标入组 228 人开始时间: 2023年7月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 228
- 试验地点
- 1
- 主要终点
- Cycle control evaluation parameter
研究概览
简要总结
As there are no recent studies conducted in Italy on the profile of this COC, the purpose of this study is to evaluate its efficacy and tolerability in a given subset of women residing in Italy that are in need of contraception. Evaluate the cycle control: breakthrough bleeding (bleeding and/or spotting between cyclically regular onset of menses) of monophasic oral contraceptive pill Effimia® (NGM250 + EE35) in a population of women residing in Italy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •All the following criteria must be met.
- •Healthy women aged between 18 and 35 years (inclusive) in need of contraception.
- •Subjects residing in Italy and having a good knowledge of the Italian language, such as to correctly understand the Informed Consent Form, the instructions for use, and to ensure potential adhesion to the study.
- •Subjects providing written Informed Consent Form.
- •Subjects willing to comply with the study protocol.
排除标准
- •Subjects who meet even one of the following criteria will be excluded from the study.
- •Subjects presenting any contraindications to the use of Combined Oral Contraceptives (COC) according to the current Summary of Product Characteristics (SmPC) of Effimia®, i.e. subjects presenting (or have ever presented) myocardial infarction, transient ischemic attack (TIA), stroke, angina pectoris, deep vein thrombosis (DVT), pulmonary embolism (PE) (or presence of blood clot in other organs than legs and lungs), any blood clotting disorder (such as protein C deficiency, protein S deficiency, antithrombin-III deficiency), or subjects that need to undergo surgery or that have to lie down for a long period of time (including the risk of previous deep vein thrombosis (DVT), arterial thromboembolism (ATE), hypertension in course of treatment and diabetes). If any of the listed conditions should appear during the use of the tested COC, the product must be stopped immediately, and the subject withdrawn from the study.
- •Subjects presenting severe diabetes with blood vessel damages, heart valve disease with complications, severe hypertension, severe hypercholesterolemia, or hypertriglyceridemia, hyperhomocysteinaemia, migraine with aura, hepatitis C (and taking medications for this condition), endometrial hyperplasia, unexplained vaginal bleeding, that are breastfeeding or pregnant or that are suspecting a pregnancy.
- •Subjects presenting (or have ever presented) any liver disease not yet recovered (liver function not yet normalized), any benign or malignant tumour of the liver, any breast or genital organs cancer (even suspected), jaundice during pregnancy or while using hormonal contraceptives.
- •Subjects presenting galactose intolerance, total lactase deficiency or glucosegalactose malabsorption syndrome.
- •Subjects presenting hypersensitivity to the active substances or to any excipients of the tested COC (e.g., norgestimate, ethinylstradiol or lactose).
- •Subjects using the following not allowed treatments during the whole study period (according to the SmPC of the Investigational Medicinal Product - IMP): treatments for tuberculosis (e.g. rifampicin), for epilepsy (e.g. primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine), for HIV and hepatitis C virus infection (protease inhibitor drugs and non-nucleoside reverse transcriptase inhibitors such as ritonavir, nevirapine, efavirenz and also ombitasvir, paritaprevir, ritonavir and dasabuvir), for fungal infections (e.g. griseofulvin), for arthritis, for osteoarthritis (etoricoxib ), for pulmonary arterial hypertension (bosentan) and St. John's wort used as an antidepressant. Medicines containing cyclosporine, the antiepileptic lamotrigine, tranexamic acid, theophylline (used to treat respiratory problems) and tizanidine (used to treat muscle pain and / or cramps) should not be taken as well.
- •Subjects who have used hormonal contraceptives in the previous month.
- •Subjects presenting a Body Mass Index - BMI ≥ 30 kg/m2 (class I obesity).
- •Subjects smoking > 15 cigarettes per day.
- •Subjects using COC off-label (e.g., for polycystic ovarian syndrome - PCOS, endometriosis, or recurrent menometrorrhagia).
- •Subjects currently taking part or who took part in clinical studies with experimental products in the previous month.
- •Subjects showing incapacity / inability to comply with the study protocol (unreliability in the intake of the product or in the completion of the diary) according to the Investigator's opinion.
结局指标
主要结局
Cycle control evaluation parameter
时间窗: 180 days
breakthrough bleeding (bleeding and/or spotting between cyclically regular onset of menses) by calculating the intermenstrual spotting occurrence rate at sixth cycle only (value to be intended as not cumulative with values from the other 5 cycles taking place during the whole study period). A comparison within group will be performed at V3 with respect to Baseline (V1)
次要结局
- Metabolic and hormonal parameters(180 days)
- Cycle control evaluation parameters(180 days)
- Global Acne Grading System (GAGS).(180 days)
- Profile of Mood State (POMS).(180 days)
- Female Sexual Function Index (FSFI).(180 days)
- Dysmenorrhea - VAS scale.(180 days)
- Compliance(180 days)
- Contraception failure rate during the 6-month treatment(180 days)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Calcinosis cutis in SSc patients treated with sodium thiosulfate assessed by biomarkers and imagingCalcinosis cutis in systemic sclerosisCTIS2023-510255-34-00Aarhus Universitetshospital75
已完成
不适用
A Prospective, Open, Multicenter Clinical Study Over 48 Weeks to Investigate Efficacy and Safety of Cell-free Autologous Conditioned Serum (ACS) in Patients with Skin Elasticity Lossack of facial skin elasticity by healthy volunteersDRKS00013014niversita¨t Hamburg Fachrichtung Kosmetikwissenschaft95
进行中（未招募）
1 期
An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrombotic therapy. - ARG-E07EUCTR2008-000730-42-FRMitsubishi Tanabe Pharma Corporation20
进行中（未招募）
不适用
Prospective multicentric open clinical study comparing the efficacy and safety of piascledine 300 plus standard treatment versus standard treatment only in patients with osteoarthritis of the knee - PRAGMA-PIAS STUDYOsteoarthritis of the kneeEUCTR2007-004973-25-PLaboratoire Expanscience300
已完成
不适用
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP-G632 Diabetic polyneuropathy (E10-E14+ with common fourth character.4)-G630 Polyneuropathy in infectious and parasitic diseases classified elsewhere-G620 Drug-induced polyneuropathyDrug-induced polyneuropathyPolyneuropathy in infectious and parasitic diseases classified elsewhereDiabetic polyneuropathy (E10-E14+ with common fourth character.4)G620G630G632PER-089-06PFIZER S.A.,